Mosunetuzumab is a type of immunotherapy called a bispecific antibody. It is designed to help your immune system find and destroy cancer cells. Specifically, mosunetuzumab binds to two different proteins: CD20, which is found on the surface of certain lymphoma (B) cells, and CD3, which is found on T-cells (a type of immune cell).

By linking these two cells together, mosunetuzumab brings your T-cells into close contact with the lymphoma cells. This activates the T-cells, causing them to attack and kill the cancerous B-cells. In clinical studies, mosunetuzumab has been shown to reduce the number of B-cells in the blood and can lead to significant responses in patients with follicular lymphoma who have already tried other treatments.

Because it activates the immune system, mosunetuzumab can also cause the release of cytokines (immune signaling molecules), which can lead to side effects such as cytokine release syndrome. The medication is given in a step-up dosing schedule to help minimize these risks.

mosunetuzumab

Common brand names

Approved use in